A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-16

Study Completion Date

2021-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this open-label, single-dose, randomized, three-treatment, three-period, four-sequence, crossover study is to evaluate the relative bioavailability of a test formulation of lofexidine granules for reconstitution (oral) and LUCEMYRA tablets under fasted conditions and to evaluate the effect of food on the relative bioavailability of lofexidine granules for reconstitution (oral) when administered under fed compared to fasted conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food

NCT05498701

Healthy

COMPLETED PHASE1

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

NCT03010631

Healthy Volunteers

COMPLETED PHASE3

A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled

NCT02044419

Healthy

COMPLETED PHASE1

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084

Healthy

COMPLETED PHASE1

Bioavailability Study of Torsemide Tablets Under Fed Conditions

NCT00654043

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Normal Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lofexidine (granules for reconstitution), fasted

Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.

Group Type EXPERIMENTAL

Lofexidine (granules for reconstitution)

Intervention Type DRUG

All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.

LUCEMYRA (lofexidine) tablets, fasted

Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours

Group Type ACTIVE_COMPARATOR

LUCEMYRA (lofexidine) tablets

Intervention Type DRUG

All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.

Lofexidine (granules for reconstitution), fed

Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.

Group Type EXPERIMENTAL

Lofexidine (granules for reconstitution)

Intervention Type DRUG

All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lofexidine (granules for reconstitution)

All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.

Intervention Type DRUG

LUCEMYRA (lofexidine) tablets

All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females, 18-50 years of age, inclusive, with a Body Mass Index (BMI) of 20.0-35.0 kg/m², inclusive.
2. Female subjects must meet at least one of the following criterion:

* Agree to abstain from sexual intercourse from screening and throughout the duration of the study.
* Have used and agree to continue to use a reliable method of contraception (e.g., condom with spermicide, IUD, hormonal contraceptives) for at least 30 days before initial dosing and throughout the duration of the study.
* Surgically sterile (bilateral oophorectomy or hysterectomy, bilateral tubal ligation or Essure® device placement at least 3 months prior to initial dosing).
* At least 1 year postmenopausal and have a documented FSH level ≥ 40 mIU/mL at screening.
3. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
4. Signed and dated informed consent form, which meets all criteria of current FDA regulations.

Exclusion Criteria

1. Females who are pregnant, lactating, or likely to become pregnant during the study.
2. History of allergy or sensitivity to lofexidine or any component of the study drug or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
3. Significant history or current evidence of chronic infectious disease, system disorders, or organ dysfunction, especially cardiovascular disorders (e.g., severe coronary insufficiency, recent myocardial infarction \[within 1 year before initial dosing\], cerebrovascular disease), respiratory disorders, congenital long QT syndrome, diabetes, hepatic or renal disorders (e.g., chronic renal failure).
4. Pulse \< 50 bpm or symptomatic bradycardia, as determined by the Investigator.
5. Clinically significant history of hypotension, as determined by the Investigator, or has a sitting/supine systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 60 mmHg, or hypertension, as determined by the Investigator, or has sitting/supine systolic blood pressure \> 190 mmHg and/or diastolic \> 95 mmHg; determined at screening.
6. Experiences reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing from a resting (sitting or supine) position; determined at screening.
7. 12-lead ECG, conducted in triplicate, considered by the Investigator to be clinically significant (e.g., second or third degree heart block, uncontrolled arrhythmia) or has a QTcF (Fridericia's correction) interval \> 440 msec in 2 of the 3 ECGs performed; determined at screening.
8. Clinically significant history or presence of any gastrointestinal disease or history of malabsorption within the last year, as determined by the Investigator.
9. History of any psychiatric disorders occurring within the last two years that required the subject to be hospitalized or treated with medication.
10. Subject has history of suicidality based on responses provided on the Columbia-Suicide Severity Rating Scale (C-SSRS), or is at risk for self-harm or harm to others based on clinical interview, at the discretion of the Investigator.
11. Ingestion of grapefruit-containing food or beverages (e.g., Fresca®) within 7 days before dosing.
12. Drug or alcohol addiction requiring treatment in the 12 months before initial dosing.
13. History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months.
14. Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
15. Positive test results for drugs of abuse (benzodiazepines, cocaine, cannabinoids/THC, opiates and at screening only: amphetamines, barbiturates, methadone and phencyclidine).

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes